Home Medicine More and more biotechs are worth less than their checking accounts

More and more biotechs are worth less than their checking accounts

66
0



Biotech’s 2021 swoon has settled into a 2022 malaise, with the closely watched XBI index now down 40% for the year. That has pushed more than 200 public companies into the unwanted territory of running a business that’s worth less than the cash they have in the bank.

The analysts at Evercore ISI trawled the numbers to find the industry’s most dire cases: companies whose enterprise value — which is market cap plus debt and minus cash — is $100 million or more below zero. There are about 30 of them, and when you add it all up, these companies have about $14 billion in cash and a cumulative market cap of $8 billion, according to Evercore ISI.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED



Previous article‘AGT’ Judge Simon Cowell Won’t Stop Tweeting About the Parmesan Song in the 2022 Auditions
Next articleSee the Crazy Ebay Price or Make Your Own